Brukinsa (zanubrutinib) — Medica
Primary central nervous system lymphoma
Initial criteria
- Patient is age ≥ 18 years
- Patient has tried at least one systemic regimen
- Medication is used in combination with autologous stem cell reinfusion
Approval duration
1 year